← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Thermalin Diabetes, Llc
Cleveland, OH
$9,206,919
Total funding
12
Grants
Funding over time
peak $3.2M · FY2009–16$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$9,206,919 · 12
By mechanism
R44$5,965,857 · 2
R43$2,986,065 · 9
R41$254,997 · 1
Investigators at Thermalin Diabetes, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Chlorolog: Production Scaling and Testing of a Fast-Acting, Ultra-stable Insulin$1,655,309
R44 · FY2014 · DK
Chlorolog: Production Scaling and Testing of a Fast-Acting, Ultra-stable Insulin$1,474,418
R44 · FY2013 · DK
Chlorolog: Production and Testing of a Fast-Acting, Ultra-stable Insulin Analog$1,339,788
R44 · FY2012 · DK
Fluorolog: A Rapid-Acting Ultra-Concentrated Insulin Formulation$1,275,297
R44 · FY2014 · DK
Optimized Receptor Binding Profile in an Ultra-Stable, Ultra-Rapid-Acting Insulin$622,539
R43 · FY2011 · DK
A Novel "Zinc-Stapled" Long-Acting Insulin Analog$423,635
R43 · FY2010 · DK
Halogenated Insulin: a fast-acting, ultra stable analog.$392,091
R43 · FY2010 · DK
Manipulating Aromaticity: characterization of an ultra-rapid insulin analog$301,734
R43 · FY2012 · DK
An Ultra-Stable Insulin Analog with Intrinsic Basal-Bolus Action$300,000
R43 · FY2014 · DK
Novel Design of a Fast-On/Fast-Off Insulin Analog for Closed-Loop Systems$299,976
R43 · FY2013 · DK
Manipulating Aromaticity: characterization of an ultra-rapid insulin analog$263,453
R43 · FY2013 · DK
Clinical Testing of an Insulin Analog$254,997
R41 · FY2009 · DK
Fluorolog: A Rapid-Acting Ultra-Concentrated Insulin Formulation$221,045
R44 · FY2015 · DK
Hexalog: A Rapid-Acting Ultra-Concentrated Insulin Formulation$164,839
R43 · FY2013 · DK
Optimizing diabetes therapy: re-engineering insulin as a biased agonist$141,297
R43 · FY2015 · DK
Enabling implantable artificial pancreas pumps with heat-stable, ultra-rapid insulin$76,501
R43 · FY2016 · DK